InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

CHAMPIONS ONCOLOGY, INC.

CSBR Clue Score27
United States Fiscal year ends April CIK 0000771856
$4.95 +2.34% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.95 −51.01% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 13 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Operating income−6.8Net income−6.9Fiscal year 2018Revenue20.2Operating income−1.4Net income−1.5EPS, diluted−0.13Fiscal year 2019Revenue27.1 +33.7%Operating income0.3Net income0.1EPS, diluted0.01Fiscal year 2020Revenue32.1 +18.7%Operating income−1.9Net income−2.1 −1,735.2%EPS, diluted−0.18 −1,900.0%Fiscal year 2021Revenue41.0 +27.8%Operating income0.4Net income0.4EPS, diluted0.02Fiscal year 2022Revenue49.1 +19.7%Operating income0.6Net income0.5 +51.4%EPS, diluted0.04 +100.0%Fiscal year 2023Revenue53.9 +9.7%Operating income−5.3Net income−5.3 −1,073.5%EPS, diluted−0.39 −1,075.0%Fiscal year 2024Revenue50.2 −6.9%Operating income−7.4Net income−7.3EPS, diluted−0.54Fiscal year 2025Revenue56.9 +13.5%Operating income4.6Net income4.7EPS, diluted0.33Fiscal year 2026Revenue59.4 +4.4%Operating income−1.1Net income−1.2 −125.0%EPS, diluted−0.08 −124.2%
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue n/a 20.2 27.1 32.1 41.0 49.1 53.9 50.2 56.9 59.4
Growth +33.7% +18.7% +27.8% +19.7% +9.7% −6.9% +13.5% +4.4%
Operating income −6.8 −1.4 0.3 −1.9 0.4 0.6 −5.3 −7.4 4.6 −1.1
Net income −6.9 −1.5 0.1 −2.1 0.4 0.5 −5.3 −7.3 4.7 −1.2
Growth −1,735.2% +51.4% −1,073.5% −125.0%
EPS, diluted n/a −0.13 0.01 −0.18 0.02 0.04 −0.39 −0.54 0.33 −0.08
Growth −1,900.0% +100.0% −1,075.0% −124.2%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2017Fiscal year 2018Operating margin−6.7%Net margin−7.3%Free cash flow margin−12.1%Fiscal year 2019Operating margin1.0%Net margin0.5%Free cash flow margin3.8%Fiscal year 2020Operating margin−6.0%Net margin−6.5%Free cash flow margin2.1%Fiscal year 2021Operating margin0.9%Net margin0.9%Free cash flow margin−12.1%Fiscal year 2022Operating margin1.2%Net margin1.1%Free cash flow margin8.4%Fiscal year 2023Operating margin−9.8%Net margin−9.9%Free cash flow margin2.0%Fiscal year 2024Operating margin−14.7%Net margin−14.5%Free cash flow margin−13.9%Fiscal year 2025Operating margin8.0%Net margin8.3%Free cash flow margin12.3%Fiscal year 2026Operating margin−1.9%Net margin−2.0%Free cash flow margin−8.5%
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating margin n/a −6.7% 1.0% −6.0% 0.9% 1.2% −9.8% −14.7% 8.0% −1.9%
Net margin n/a −7.3% 0.5% −6.5% 0.9% 1.1% −9.9% −14.5% 8.3% −2.0%
Free cash flow margin n/a −12.1% 3.8% 2.1% −12.1% 8.4% 2.0% −13.9% 12.3% −8.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−2.8Capital expenditure−0.8Free cash flow−3.6Fiscal year 2018Operating cash flow−1.2Capital expenditure−1.2Free cash flow−2.5Fiscal year 2019Operating cash flow1.9Capital expenditure−0.8Free cash flow1.0Fiscal year 2020Operating cash flow2.9Capital expenditure−2.2Free cash flow0.7 −33.4%Fiscal year 2021Operating cash flow−1.7Capital expenditure−3.3Free cash flow−5.0 −824.4%Fiscal year 2022Operating cash flow6.5Capital expenditure−2.4Free cash flow4.1Buybacks0.0Fiscal year 2023Operating cash flow4.0Capital expenditure−2.9Free cash flow1.1 −73.3%Buybacks−0.1Fiscal year 2024Operating cash flow−6.1Capital expenditure−0.8Free cash flow−7.0 −733.9%Buybacks−0.6Fiscal year 2025Operating cash flow7.4Capital expenditure−0.4Free cash flow7.0Buybacks0.0Fiscal year 2026Operating cash flow−4.5Capital expenditure−0.6Free cash flow−5.0 −172.0%
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −2.8 −1.2 1.9 2.9 −1.7 6.5 4.0 −6.1 7.4 −4.5
Capital expenditure −0.8 −1.2 −0.8 −2.2 −3.3 −2.4 −2.9 −0.8 −0.4 −0.6
Free cash flow −3.6 −2.5 1.0 0.7 −5.0 4.1 1.1 −7.0 7.0 −5.0
Growth −33.4% −824.4% −73.3% −733.9% −172.0%
Buybacks n/a n/a n/a n/a n/a 0.0 −0.1 −0.6 0.0 n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2017Cash3.3Shareholders’ equity0.4Fiscal year 2018Cash0.9Shareholders’ equity0.0Fiscal year 2019Cash3.2Shareholders’ equity2.1Fiscal year 2020Cash8.3Shareholders’ equity5.1Fiscal year 2021Cash4.7Shareholders’ equity7.4Fiscal year 2022Cash9.0Shareholders’ equity9.1Fiscal year 2023Cash10.1Shareholders’ equity4.6Fiscal year 2024Cash2.6Shareholders’ equity−1.9Fiscal year 2025Cash9.8Shareholders’ equity3.8Fiscal year 2026Cash4.9Shareholders’ equity3.9
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash 3.3 0.9 3.2 8.3 4.7 9.0 10.1 2.6 9.8 4.9
Shareholders’ equity 0.4 0.0 2.1 5.1 7.4 9.1 4.6 −1.9 3.8 3.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending April, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 30 Apr 2017 FY2018 30 Apr 2018 FY2019 30 Apr 2019 FY2020 30 Apr 2020 FY2021 30 Apr 2021 FY2022 30 Apr 2022 FY2023 30 Apr 2023 FY2024 30 Apr 2024 FY2025 30 Apr 2025 FY2026 30 Apr 2026
Revenue and profit
n/a 20.2 27.1 32.1 41.0 49.1 53.9 50.2 56.9 59.4
Growth +33.7% +18.7% +27.8% +19.7% +9.7% −6.9% +13.5% +4.4%
n/a n/a n/a 17.0 21.4 23.6 29.5 29.4 28.4 30.9
4.3 4.4 4.8 5.9 7.2 9.4 11.5 9.5 6.8 9.1
5.0 4.1 4.7 6.6 6.5 9.1 10.2 11.1 9.3 11.2
−6.8 −1.4 0.3 −1.9 0.4 0.6 −5.3 −7.4 4.6 −1.1
Growth −811.5% +65.8% −965.9% −125.0%
−6.9 −1.4 0.2 −2.0 0.4 0.6 −5.3 −7.3 4.6 −0.9
0.0 0.0 0.1 0.1 0.1 0.0 0.1 −0.0 −0.1 0.2
−6.9 −1.5 0.1 −2.1 0.4 0.5 −5.3 −7.3 4.7 −1.2
Growth −1,735.2% +51.4% −1,073.5% −125.0%
Per share
n/a −0.13 0.01 −0.18 0.03 0.04 −0.39 −0.54 0.34 −0.08
n/a −0.13 0.01 −0.18 0.02 0.04 −0.39 −0.54 0.33 −0.08
Growth −1,900.0% +100.0% −1,075.0% −124.2%
n/a 11.0 11.3 11.8 13.1 13.2 13.5 13.5 13.7 13.8
n/a 11.0 14.1 11.8 14.6 14.2 13.5 13.5 14.3 13.8
Growth +28.3% −16.0% +23.1% −2.8% −4.4% +0.0% +5.3% −3.0%

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 7.7% a year over five years.
  • The diluted share count fell 5.1% in five years, so buybacks did some of the work per share.
  • Operating margin is down 2.8 points on five years ago, at -1.9%.
  • A net loss in 6 of 10 years on file.